BACKGROUND AND AIM: The purpose of this study was to assess the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for hepatocellular @entity652 . METHODS: We performed percutaneous RF ablation in 10 @entity1 with pathologically proven hepatocellular @entity652 . Eight @entity1 were asymptomatic and two @entity1 had a recurrent @entity5 after surgical resection. The size of the @entity5 was 2.25 +/- 0.76 cm (range: 1.5-4.5 cm) in the largest diameter. All ablation procedures were percutaneously performed with an internally cooled RF electrode system under ultrasound (US) guidance. We evaluated the therapeutic efficacy and safety of the procedure by clinical follow-up data with regular follow-up computed tomography (CT) for 2-35 months (mean, 17.5 months). RESULTS: All @entity1 well tolerated percutaneous RF ablation procedure without any incident. Contrast-enhanced CT (n = 7) or contrast-enhanced US (n = 3) obtained immediately (<24 h) after the procedure revealed complete ablation of the @entity5 in all cases. There was no case of @entity5 progression or new recurrence during the follow-up period. We found neither procedure-related mortality nor major complication requiring specific treatment. CONCLUSION: Percutaneous RF ablation of hepatocellular @entity652 without overt complication can be a new potential alternative to close imaging follow-up or elective surgery.

Percutaneous radiofrequency ablation of hepatocellular @entity652 : initial experience in 10 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'adenoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'local tumor', 'tumors']
@entity1 :: (9606,Species) :: ['patients']
